The Discovery Process Chemistry (DPC) Model: A Cross-Pharma Perspective

Discovery Process Chemistry (DPC) has emerged as a critical bridge between discovery chemistry and chemical development that allows more seamless progression of drug candidates to the clinic. DPC aims to accelerate projects by integrating SAR-enabling methodologies, scalable route design to inform later campaigns, and early material delivery. Case studies from MSD, Johnson & Johnson, and AstraZeneca highlight how this model can drive innovation and mitigate risks at the interface between medicinal and process chemistry groups.